Bloomberg reports, Pfizer is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.
Pfizer may not get a great shot at buying AstraZeneca this fall--but it's preparing to give it a try.
That domicile is a key factor, of course, given Pfizer's ($PFE) desire for a deal with tax breaks on the side. Actavis ($ACT) moved its nominal headquarters to Dublin when it bought Warner Chilcott last year.
That deal--and its subsequent buyout of U.S.-based Forest Laboratories--also built up Actavis' business in branded pharmaceuticals. So in addition to the company's large portfolio of generic meds, Actavis would bring along a few notable brands, and some newly approved meds.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity